# Phase III Study of ISU302 in Patients With Type 1 Gaucher Disease

> **NCT02770625** · PHASE3 · COMPLETED · sponsor: **ISU Abxis Co., Ltd.** · enrollment: 8 (actual)

## Conditions studied

- Gaucher Disease, Type 1

## Interventions

- **DRUG:** ISU302

## Key facts

- **NCT ID:** NCT02770625
- **Lead sponsor:** ISU Abxis Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2013-03
- **Final completion:** 2014-08
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2017-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02770625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02770625, "Phase III Study of ISU302 in Patients With Type 1 Gaucher Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02770625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*